TipRanks
Infant Bacterial Therapeutics AB (DE:9IB)
FRANKFURT:9IB
Germany Market
9IB
Infant Bacterial Therapeutics AB
RESEARCH TOOLSreports

Infant Bacterial Therapeutics AB (9IB) Income Statement

4 Followers

Infant Bacterial Therapeutics AB Income Statement

Last quarter (Q2 2026), Infant Bacterial Therapeutics AB's total revenue was kr0.00, a decrease of ― from the same quarter last year. In Q2, Infant Bacterial Therapeutics AB's net income was kr-29.73M. See Infant Bacterial Therapeutics AB’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
kr 0.00kr 4.00Kkr 77.00Kkr 12.00Kkr 0.00
Gross Profit
kr 0.00kr 4.00Kkr 77.00Kkr 12.00Kkr 0.00
Operating Expenses
kr 61.95Mkr 139.90Mkr 134.69Mkr 65.81Mkr 44.58M
Depreciation and Amortization
kr 816.00Kkr 145.34Mkr 134.62Mkr 816.00Kkr 816.00K
EBITDA
kr -68.18Mkr -136.91Mkr 11.55Mkr -64.34Mkr -43.76M
Operating Income
kr -61.95Mkr -139.90Mkr -134.62Mkr -65.81Mkr -44.58M
Other Income/Expenses
kr -3.21Mkr 3.00Mkr 11.55Mkr 357.00Kkr -413.00K
Pretax Income
kr -65.17Mkr -136.91Mkr -123.07Mkr -65.45Mkr -44.99M
Net Income
kr -65.17Mkr -136.91Mkr -123.07Mkr -65.45Mkr -44.99M
Per Share Metrics
Basic EPS
kr -4.84kr -10.16kr -9.95kr -5.83kr -4.01
Diluted EPS
kr -4.84kr -10.16kr -9.95kr -5.83kr -4.01
Weighted Average Shares Outstanding
 13.47M 13.47M 12.36M 11.23M 11.23M
Weighted Average Shares Outstanding (Diluted)
 13.47M 13.47M 12.36M 11.23M 11.23M
Currency in SEK

Infant Bacterial Therapeutics AB Earnings and Revenue History